Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 4 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready
Shanghai Resthetic Bio Co. Ltd. currently manages 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. This workload is distributed across 5 distinct examiners, indicating a highly fragmented prosecution landscape where each examiner handles a single action. The involvement of 4 distinct art units further suggests that the portfolio spans several specialized sub-sectors within the broader biotechnology field. Practitioners should prepare for diverse examination styles across these 4 distinct art units.
SAEED, ALI S is identified as the busiest examiner for the company, and this individual is responsible for 1 pending office action. This parity between the busiest examiner and the overall distribution across the 5 distinct examiners highlights a lack of examiner concentration. Because each of the 5 pending office actions is assigned to a different person, the company cannot rely on a single relationship to resolve its current patent hurdles. Instead, the strategy must be tailored to the specific tendencies of each distinct examiner involved in the 4 distinct art units.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| Multi-statute (no §101) | 3 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAEED, ALI S | 1 | 31.3% | +35.8% |
| MOLOYE, TITILAYO | 1 | 62.5% | +47.9% |
| MOORE, JOHN DAVID | 1 | 64.2% | +24.8% |
| ARNOLD, ERNST V | 1 | 48.2% | +12.9% |
| STAVROU, CONSTANTINA E | 1 | 43.7% | +36.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18262232 | CARTILAGE TISSUE ENGINEERING COMPLEX AND USE THEREOF | ARNOLD, ERNST V | 23d |
| 18262224 | EAR CARTILAGE TISSUE ENGINEERING COMPLEX AND USE THEREOF | MOORE, JOHN DAVID | — |
| 18258630 | TISSUE ENGINEERED BONE GRAFT USED IN INFERIOR TURBINATE RECONSTRUCTION | STAVROU, CONSTANTINA E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18262232 | CARTILAGE TISSUE ENGINEERING COMPLEX AND USE THEREOF | ARNOLD, ERNST V | 23d |
| 18262216 | METHOD FOR REALIZING CARTILAGE REGENERATION BY MEANS OF INOCULATING GEL CARTILAGE INTO FRAME STRUCTURE | SAEED, ALI S | 26d |
| 18262588 | LARGE APERTURE-BASED TISSUE ENGINEERING SCAFFOLD AND USE THEREOF | MOLOYE, TITILAYO | 76d |
| 18262224 | EAR CARTILAGE TISSUE ENGINEERING COMPLEX AND USE THEREOF | MOORE, JOHN DAVID | — |
| 18258630 | TISSUE ENGINEERED BONE GRAFT USED IN INFERIOR TURBINATE RECONSTRUCTION | STAVROU, CONSTANTINA E | — |
| Art Unit | Apps |
|---|---|
| 1632 | 2 |
| 1616 | 1 |
| 1638 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18262216 | METHOD FOR REALIZING CARTILAGE REGENERATION BY MEANS OF INOCULATING GEL CARTILAGE INTO FRAME STRUCTURE | SAEED, ALI S | 1616 | §103Other | Final Rejection | 26d | Pending | Jan 24, 2024 |
| 18262588 | LARGE APERTURE-BASED TISSUE ENGINEERING SCAFFOLD AND USE THEREOF | MOLOYE, TITILAYO | 1632 | §103 | Non-Final OA | 76d | Pending | Jul 24, 2023 |
| 18262224 | EAR CARTILAGE TISSUE ENGINEERING COMPLEX AND USE THEREOF | MOORE, JOHN DAVID | 1638 | §103§112Other | Non-Final OA | — | Pending | Jul 20, 2023 |
| 18262232 | CARTILAGE TISSUE ENGINEERING COMPLEX AND USE THEREOF | ARNOLD, ERNST V | 1613 | §103§112 | Non-Final OA | 23d | Pending | Jul 20, 2023 |
| 18258630 | TISSUE ENGINEERED BONE GRAFT USED IN INFERIOR TURBINATE RECONSTRUCTION | STAVROU, CONSTANTINA E | 1632 | §102§103§112 | Final Rejection | — | Pending | Jun 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial